Muscarinic m4 receptor activation by some atypical antipsychotic drugs

European Journal of Pharmacology

Volumn 321, Issue 3, 1997, Pages 349-354

  Zeng, Xiang Ping ^a   Le, Fei ^a   Richelson, Elliott ^a  

^a MAYO CLINIC   (United States)

Author keywords

Atypical; CAMP; Chinese hamster ovary cell; Clozapine; Muscarinic m4 receptor; Neuroleptic; Neuroleptics; Rat; Striatum; Typical

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; CYCLIC AMP; FLUPERLAPINE; FLUPHENAZINE; FORSKOLIN; HALOPERIDOL; MOLINDONE; MUSCARINIC M4 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RECEPTOR SUBTYPE; RILAPINE; RISPERIDONE; SERTINDOLE; TENILAPINE; THIORIDAZINE; TIOTIXENE; ZIPRASIDONE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHO CELL; CONTROLLED STUDY; CORPUS STRIATUM; DRUG MECHANISM; GENE EXPRESSION; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; CHO CELLS; CORPUS STRIATUM; CRICETINAE; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; FORSKOLIN; MALE; RATS; RATS, WISTAR; RECEPTOR, MUSCARINIC M4; RECEPTORS, MUSCARINIC;

EID: 0031043685     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(96)00956-9     Document Type: Article

References (37)

1. Baldessarini, R.J. and F.R. Frankenberg, 1991, Clozapine. A novel antipsychotic agent, New Engl. J. Med. 324, 746.
2. Bernard, V., E. Normand and B. Bloch, 1992, Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes, J. Neurosci. 12, 3591.
3. Bolden, C., B. Cusack and E. Richelson, 1992, Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells, J. Pharmacol. Exp. Ther. 260, 576.
4. Bonner, T.I., 1989, New subtypes of muscarinic acetylcholine receptors, Trends Pharmacol. Sci. (Suppl.) 11.
5. Coward, D.M., 1992, General pharmacology of clozapine, Br. J. Psychiatry 160 (Suppl. 17), 5.
6. Dittman, A.H., J.P. Weber, T.R. Hinds, E-J. Choi, J.C. Migeon, N.M. Nathanson and D.R. Storm. 1994, A novel mechanism for coupling of m4 muscarinic acetylcholine receptors to calmodulin-sensitive adenylyl cyclases: crossover from G-protein-coupled inhibition to stimulation, Biochemistry 33, 943.
7. Fosbraey, P., M.F. Hird and E.S. Johnson, 1980, The effects of some dopamine antagonists on cholinergic mechanisms in the guinea-pig ileum, J. Auton. Pharmacol. 1, 17.
8. Gorell, J.M. and B. Czarnecki, 1986, Pharmacologic evidence for direct dopaminergic regulation of striatal acetylcholine release, Life Sci. 38, 2239.
9. Herrling, P.L. and B. Misbach-Lesenne, 1982, Effects of clozapine in a selective muscarinic bioassay and on single cells of the rat hippocampus, Naunyn-Schmiedeberg's Arch. Pharmacol. 320, 20.
10. Hersch, S.M., C.-A. Gutekunst, H.D. Rees, C.J. Heilman and A.I. Levey, 1994. Distribution of m1-m4 muscarinic receptor proteins in the rat striatum: light and electron microscopic immunocytochemistry using subtype-specific antibodies, J. Neurosci. 14, 3351.
11. Jones, S.V.P., C.J. Heilman and M.R. Brann, 1991, Functional responses of cloned muscarinic receptors expressed in CHO-K1 cells, Mol. Pharmacol. 40, 242.
12. Klieser, E., E. Lehmann, E. Kinzler, C. Wurthmann and K. Heinrich, 1995, Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia, J. Clin. Psychopharmacol. 15, 45S.
13. Lassen, J.B., 1979, Inhibition of apomorphine-induced climbing in mice by cholinergic drugs and neuroleptics, Acta Pharmacol. Toxicol. 45, 161.
14. Levey, A.I., C.A. Kitt, W.F. Simonds, D.L. Price and M.R. Brann, 1991, Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies, J. Neurosci. 11, 3218.
15. Meltzer, H.Y., 1991, The mechanism of action of novel antipsychotic drugs, Schizophr. Bull. 17, 263.
16. Meltzer, H.Y., 1992, Treatment of the neuroleptic non-responsive schizophrenia patient, Schizophr. Bull. 18, 515.
17. Meltzer, H.Y., 1994, An overview of the mechanism of action of clozapine, J. Clin. Psychiatry 55 (Suppl. B), 47.
18. Meltzer, H.Y., 1995, Atypical antipsychotic drugs, in: Psychopharmacology: the Fourth Generation of Progress, ed. F.E. Bloom and D.J. Kupfer (Raven Press, New York, NY) p. 1277.
19. i values, J. Pharmacol. Exp. Ther. 251, 238.
20. Meltzer, H.Y., B.L. Chai, P.A. Thompson and B.K. Yamamoto, 1994, Effect of scopolamine on the efflux of dopamine and its metabolites after clozapine, haloperidol or thioridazine, J. Pharmacol. Exp. Ther. 268, 1452.
21. i-2, J. Biol. Chem. 269, 9767.
22. Migler, B.M., E.J. Warawa and J.B. Malick, 1993, Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug, Psychopharmacology 112, 299.
23. Moore, N.A., N.C. Tye, M.S. Axton and F.C. Risius, 1992, The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent, J. Pharmacol. Exp. Ther. 262, 545.
24. 3H]tryptamine receptor in human brain: Kinetics of distribution, and pharmacologic profile, J. Neurochem. 63, 1052.
25. Ögren, S.O., 1992, Pharmacology of atypical neuroleptic drugs: relevance for muscarinic mechanisms in schizophrenia, Presented at the American College of Neuropsychopharmacology annual meeting, San Juan, Puerto Rico.
26. Pfenning, M.A. and E. Richelson, 1990, Methods for studying receptors with cultured cells of Nervous tissue origin, in: Methods in Neurotransmitter Receptor Analysis, ed. H.I. Yamamura et al. (Raven Press, New York, NY) p. 147.
27. Richelson, E., 1991, The molecular biology and neuropsychopharmacology of the muscarinic acetylcholine receptors, Annu. Rev. Psychiatry 10, 423.
28. Rivest, R. and C.A. Marsden, 1991, Muscarinic receptor antagonists attenuate the increase in accumbens and striatum dopamine metabolism but not by haloperidol, Br. J. Pharmacol. 104, 234.
29. Saller, C.F. and A.I. Salama, 1993, Seroquel: biochemical profile of a potential atypical antipsychotic, Psychopharmacology 112, 285.
30. Snyder, S., D. Greenberg and H.I. Yamamura, 1974, Antischizophrenic drugs and brain cholinergic receptors - affinity for muscarinic sites predicts extrapyramidal effects, Arch. Gen. Psychiatry 31, 58.
31. Stille, G., H. Lauener and E. Eichenberger, 1971, The pharmacology of 8-chloro-11(4-methyl-1-piperazinyl)-5H-dibenzo(B,E)(1,4) diazepine (clozapine), Il Farmaco. 26, 603.
32. Swerdlow, N.R., D. Zisook and N. Taaid, 1994, Seroquel (ICI 204,636) restores prepulse inhibition of acoustic startle in apomorphine-treated rats: similarities to clozapine, Psychopharmacology 114, 675.
33. Tandon, R. and J.F. Greden, 1989, Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia, Arch. Gen. Psychiatry 46, 745.
34. Van Tol, H.H.M., J.R. Bunzow, H.C. Guan, R.K. Sunahara, P. Seeman, H.B. Niznik and O. Civelli, 1991, Cloning of the gene for human D4 receptor with high affinity for the antipsychotic clozapine, Nature 350, 610.
35. Wong, C.-S., Y.-F. Su, W.D. Watkins and K.-J. Chang, 1994, Opioid agonist binding affinity is increased by magnesium in the presence of guanosine diphosphate but decreased by magnesium in the presence of guanyl-5′-yl imidodiphosphate, J. Pharmacol. Exp. Ther. 268, 653.
36. Yasuda, R.P., W. Ciesla, L.R. Flores, S.J. Wall, M. Li, S.A. Satkus, J.S. Weisstein, B.V. Spagnola and B.B. Wolfe, 1993, Development of antisera selective for m4 and m5 muscarinic cholinergic receptors: distribution of m4 and m5 receptors in rat brain, Mol. Pharmacol. 43, 149.
37. Zorn, S.H., S.B. Jones, K.M. Ward and D.R. Liston, 1994, Clozapine is a potent and selective muscarinic M4 receptor agonist, Eur. J. Pharmacol. Mol. Pharmacol. Sect. 269, R1.